Publications by authors named "Isabel R Preeshagul"

Article Synopsis
  • A study compared the effectiveness of single-agent PD-(L)1 blockade therapy (IO) versus a combination of chemotherapy and PD-(L)1 blockade (Chemotherapy-IO) in patients with advanced lung adenocarcinomas (LUADs) who had PD-L1 expression of 1% or more.
  • The results showed that Chemotherapy-IO led to a higher objective response rate (44% vs 35%) and longer progression-free survival compared to IO alone, particularly in patients with higher PD-L1 expression.
  • However, only never-smokers with PD-L1 expression of 50% or more showed a significant survival benefit from the combination treatment, while patients with very high PD-L1 expression (
View Article and Find Full Text PDF

Purpose: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance.

Patients And Methods: We conducted two prospective, phase I/II trials assessing combination osimertinib and dacomitinib to address on-target resistance in the primary and acquired resistance settings.

View Article and Find Full Text PDF

Unlabelled: Patients with mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Preclinical studies suggest that tumors with both -sensitizing alteration and acquired second-site EGFR resistance alterations after treatment with osimertinib retain sensitivity to second-generation EGFR TKIs. We hypothesized that dacomitinib, a pan-human epidermal growth factor receptor TKI, may be effective in this setting.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effectiveness of using DNA hybridization (ISH) alongside p16 immunohistochemistry (IHC) in diagnosing human papillomavirus (HPV) in oropharyngeal carcinoma (OPSCC).
  • Among 50 patients, p16 IHC showed a higher positivity rate (72.9%) compared to DNA-ISH, which had lower sensitivity and agreement with p16 IHC results.
  • The findings suggest that p16 IHC is a reliable standalone test for HPV detection in OPSCC, as the combination with DNA-ISH did not significantly enhance diagnostic accuracy.
View Article and Find Full Text PDF

The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade.

View Article and Find Full Text PDF

Purpose: Treatment with PD-(L)1 blockade can produce remarkably durable responses in patients with non-small cell lung cancer (NSCLC). However, a significant fraction of long-term responders ultimately progress and predictors of late progression are unknown. We hypothesized that circulating tumor DNA (ctDNA) analysis of long-term responders to PD-(L)1 blockade may differentiate those who will achieve ongoing benefit from those at risk of eventual progression.

View Article and Find Full Text PDF

The spectrum and evolution of proliferation rates in stage IV lung carcinoids is poorly defined. In particular, there are limited data on the prevalence and characteristics of tumors exceeding the standard upper proliferative criteria-as defined largely based on early-stage carcinoids-in metastatic setting. Sixty-six patients with stage IV lung carcinoids were identified, and all evaluable samples (n = 132; mean 2 samples per patient) were analyzed for mitotic counts and Ki-67 rate.

View Article and Find Full Text PDF

The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have been approved for non-small cell lung cancer (NSCLC), this review focuses on atezolizumab, its landmark studies, and ongoing trials.

View Article and Find Full Text PDF

The treatment of multiple myeloma (MM) has dramatically changed in the last decade due to the introduction of the immunomodulatory drugs (IMIDs) and proteasome inhibitors, otherwise known as the novel agents. Prior to the advent of the novel agents, the gold standard of treatment had been high-dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) for eligible candidates. Given the remarkable activity of the novel agents, and the significant morbidity of HDT/ASCT, the role of stem cell transplantation has now come into question.

View Article and Find Full Text PDF